QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

This Article Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dewey, S. L. Articles by Wolf, A. P. Search for Related Content PubMed PubMed Citation Articles by Dewey, S. L. Articles by Wolf, A. P.

 Previous Article  |  Next Article 

Journal of Neuroscience, Vol 12, 3773-3780, Copyright © 1992 by Society for Neuroscience

ARTICLE

GABAergic inhibition of endogenous dopamine release measured in vivo with 11C-raclopride and positron emission tomography

SL Dewey, GS Smith, J Logan, JD Brodie, DW Yu, RA Ferrieri, PT King, RR MacGregor, TP Martin and AP Wolf
Department of Chemistry, Brookhaven National Laboratory, Upton, New York 11973.

Extensive neuroanatomical, neurophysiological, and behavioral evidence demonstrates that GABAergic neurons inhibit endogenous dopamine release in the mammalian corpus striatum. Positron emission tomography (PET) studies in adult female baboons, using the dopamine D2-specific radiotracer 11C-raclopride, were undertaken to assess the utility of this imaging technique for measuring these dynamic interactions in vivo. 11C-raclopride binding was imaged prior to and following the administration of either gamma-vinyl-GABA (GVG), a specific suicide inhibitor of the GABA-catabolizing enzyme GABA transaminase, or lorazepam, a clinically prescribed benzodiazepine agonist. Striatal 11C- raclopride binding increased following both GVG and lorazepam administration. This increase exceeded the test/retest variability of 11C-raclopride binding observed in the same animals. These findings confirm that changes in endogenous dopamine concentrations resulting from drug-induced potentiation of GABAergic transmission can be measured with PET and 11C-raclopride. Finally, this new strategy for noninvasively evaluating the functional integrity of neurophysiologically linked transmitter systems with PET supports its use as an approach for assessing the multiple mechanisms of drug action and their consequences in the human brain.

This article has been cited by other articles:

				M. A. Nader and P. W. Czoty PET Imaging of Dopamine D2 Receptors in Monkey Models of Cocaine Abuse: Genetic Predisposition Versus Environmental Modulation Am J Psychiatry, August 1, 2005; 162(8): 1473 - 1482. [Abstract] [Full Text] [PDF]

				K. K. Yoder, C. Wang, and E. D. Morris Change in Binding Potential as a Quantitative Index of Neurotransmitter Release Is Highly Sensitive to Relative Timing and Kinetics of the Tracer and the Endogenous Ligand J. Nucl. Med., May 1, 2004; 45(5): 903 - 911. [Abstract] [Full Text] [PDF]

				D. H. Zald, I. Boileau, W. El-Dearedy, R. Gunn, F. McGlone, G. S. Dichter, and A. Dagher Dopamine Transmission in the Human Striatum during Monetary Reward Tasks J. Neurosci., April 28, 2004; 24(17): 4105 - 4112. [Abstract] [Full Text] [PDF]

				D. L. Alexoff, P. Vaska, D. Marsteller, T. Gerasimov, J. Li, J. Logan, J. S. Fowler, N. B. Taintor, P. K. Thanos, and N. D. Volkow Reproducibility of 11C-Raclopride Binding in the Rat Brain Measured with the MicroPET R4: Effects of Scatter Correction and Tracer Specific Activity J. Nucl. Med., May 1, 2003; 44(5): 815 - 822. [Abstract] [Full Text] [PDF]

				A. D Gee Neuropharmacology and drug development: Imaging in clinical neuroscience Br. Med. Bull., March 1, 2003; 65(1): 169 - 177. [Abstract] [Full Text] [PDF]

				L. N. Yatham, P. F. Liddle, R. W. Lam, I-S. Shiah, C. Lane, A. J. Stoessl, V. Sossi, and T. J. Ruth PET Study of the Effects of Valproate on Dopamine D2 Receptors in Neuroleptic- and Mood-Stabilizer-Naive Patients With Nonpsychotic Mania Am J Psychiatry, October 1, 2002; 159(10): 1718 - 1723. [Abstract] [Full Text] [PDF]

				J. C. Price, W. C. Drevets, J. Ruszkiewicz, P. J. Greer, V. L. Villemagne, L. Xu, S. Mazumdar, M. N. Cantwell, and C. A. Mathis Sequential H215O PET Studies in Baboons: Before and After Amphetamine J. Nucl. Med., August 1, 2002; 43(8): 1090 - 1100. [Abstract] [Full Text] [PDF]

				H. Tsukada, N. Harada, S. Nishiyama, H. Ohba, and T. Kakiuchi Cholinergic Neuronal Modulation Alters Dopamine D2 Receptor Availability In Vivo by Regulating Receptor Affinity Induced by Facilitated Synaptic Dopamine Turnover: Positron Emission Tomography Studies with Microdialysis in the Conscious Monkey Brain J. Neurosci., September 15, 2000; 20(18): 7067 - 7073. [Abstract] [Full Text] [PDF]

				N. D. Volkow and J. S. Fowler Addiction, a Disease of Compulsion and Drive: Involvement of the Orbitofrontal Cortex Cereb Cortex, March 1, 2000; 10(3): 318 - 325. [Abstract] [Full Text] [PDF]

				N. D. Volkow, Gene.-J. Wang, J. S. Fowler, S. J. Gatley, J. Logan, Y.-S. Ding, R. Hitzemann, and N. Pappas Dopamine Transporter Occupancies in the Human Brain Induced by Therapeutic Doses of Oral Methylphenidate Am J Psychiatry, October 1, 1998; 155(10): 1325 - 1331. [Abstract] [Full Text]

				A. Breier, T.-P. Su, R. Saunders, R. E. Carson, B. S. Kolachana, A. de Bartolomeis, D. R. Weinberger, N. Weisenfeld, A. K. Malhotra, W. C. Eckelman, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method PNAS, March 18, 1997; 94(6): 2569 - 2574. [Abstract] [Full Text] [PDF]

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help